Oric Pharmaceuticals (NASDAQ:ORIC – Get Free Report) had its price objective cut by equities researchers at Wells Fargo & Company from $25.00 to $23.00 in a research report issued on Wednesday, Benzinga reports. The firm presently has an “overweight” rating on the stock. Wells Fargo & Company‘s price target would indicate a potential upside of 198.70% from the company’s previous close.
Several other analysts also recently commented on the stock. BTIG Research reiterated a “buy” rating and issued a $26.00 target price on shares of Oric Pharmaceuticals in a report on Tuesday. HC Wainwright boosted their price target on shares of Oric Pharmaceuticals from $25.00 to $27.00 and gave the stock a “buy” rating in a report on Monday, August 10th. Leerink Partners assumed coverage on shares of Oric Pharmaceuticals in a report on Monday, October 5th. They set an “outperform” rating and a $26.00 price target on the stock. Stifel Nicolaus upped their price objective on shares of Oric Pharmaceuticals from $14.00 to $18.00 and gave the stock a “buy” rating in a research report on Monday, October 26th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Oric Pharmaceuticals in a research note on Thursday, October 15th. Thirteen research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $20.18.
View Our Latest Stock Analysis on ORIC
Oric Pharmaceuticals Price Performance
Oric Pharmaceuticals (NASDAQ:ORIC – Get Free Report) last posted its quarterly earnings data on Monday, November 16th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.05). On average, analysts anticipate that Oric Pharmaceuticals will post -1.58 earnings per share for the current year.
Insider Buying and Selling at Oric Pharmaceuticals
In related news, CFO Dominic Piscitelli sold 77,000 shares of the business’s stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $13.69, for a total value of $1,054,130.00. Following the transaction, the chief financial officer directly owned 69,828 shares of the company’s stock, valued at approximately $955,945.32. The trade was a 52.44% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 105,000 shares of company stock valued at $1,432,952. 5.70% of the stock is currently owned by insiders.
Institutional Trading of Oric Pharmaceuticals
Several hedge funds have recently added to or reduced their stakes in the stock. Integrated Wealth Concepts LLC bought a new stake in shares of Oric Pharmaceuticals in the 2nd quarter worth approximately $38,000. Quantbot Technologies LP bought a new position in Oric Pharmaceuticals during the second quarter valued at $46,000. Mirae Asset Global Investments Co. Ltd. bought a new position in Oric Pharmaceuticals during the third quarter valued at $71,000. Bellevue Group AG bought a new position in Oric Pharmaceuticals during the third quarter valued at $75,000. Finally, Canada Pension Plan Investment Board purchased a new stake in Oric Pharmaceuticals in the second quarter worth $128,000. Institutional investors own 95.05% of the company’s stock.
Oric Pharmaceuticals News Roundup
Here’s some of the latest news about ORIC:
- Positive Sentiment: BTIG Research reaffirmed its “Buy” rating, and Citigroup was reported to see strong potential for price appreciation. BTIG Research Reaffirms Buy Rating Citigroup Forecasts Strong Price Appreciation
- Neutral Sentiment: Analysts’ reported consensus price target is $21.33, well above the cited $7.70 share price, but a target is an estimate rather than a guarantee. Consensus Price Target
- Negative Sentiment: HC Wainwright cut its target from $27 to $20 while maintaining a “Buy” rating; Wells Fargo lowered its target from $25 to $23 but retained an “Overweight” rating. The reductions may temper optimism, despite both firms remaining bullish. HC Wainwright Rating Wells Fargo Rating
Oric Pharmaceuticals Company Profile
Oric Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its research centers on therapies intended to address treatment resistance and improve outcomes for people with tumors that have become difficult to treat. The company’s drug candidates have included ORIC-114, a targeted therapy designed to inhibit EGFR and HER2 alterations, and ORIC-944, which targets the PRC2 pathway and has been investigated for prostate cancer. These programs are investigational and are not approved medicines.
Further Reading
- Five stocks we like better than Oric Pharmaceuticals
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Oric Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oric Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
